# Trial of Gemcitabine, Carboplatin, and Sorafenib in Chemotherapy-naive Patients With Advanced/Metastatic Bladder Carcinoma

> **NCT00461851** · PHASE2 · COMPLETED · sponsor: **Yale University** · enrollment: 17 (actual)

## Conditions studied

- Bladder Cancer

## Interventions

- **DRUG:** Gemcitabine
- **DRUG:** Carboplatin
- **DRUG:** Sorafenib

## Key facts

- **NCT ID:** NCT00461851
- **Lead sponsor:** Yale University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-03
- **Primary completion:** 2013-08
- **Final completion:** 2013-08
- **Target enrollment:** 17 (ACTUAL)
- **Last updated:** 2017-12-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00461851

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00461851, "Trial of Gemcitabine, Carboplatin, and Sorafenib in Chemotherapy-naive Patients With Advanced/Metastatic Bladder Carcinoma". Retrieved via AI Analytics 2026-07-27 from https://api.ai-analytics.org/clinical/NCT00461851. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*